Navitoclax (ABT-263)

目录号：S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格 价格 库存 购买数量  
In DMSO RMB 3285.53 现货
RMB 975.71 现货
RMB 1631.61 现货
RMB 3016.58 现货
RMB 7950.36 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献91篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中Ki分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。
靶点
Bcl-xL [1]
(Cell-free assay)		 Bcl-2 [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，Ki分别为0.5, 1和1 nM。[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。[2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NYfmR4l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC2Olkh|ryP MmnsV2FPT0WU
MV-4-11 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLITWM2OD1yLkCxOVg3KM7:TR?= MWLTRW5ITVJ?
NKM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX4TWM2OD1yLkCxOlk6KM7:TR?= NEXG[WJUSU6JRWK=
ML-2 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG4UXNKSzVyPUCuNFE6QDNizszN NYLtTXZTW0GQR1XS
BV-173 M4i2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMcotsUUN3ME2wMlAzOzF2IN88US=> NWLLPIs1W0GQR1XS
RS4-11 NIT2RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DtWWlEPTB;MD6wNlU5PyEQvF2= M{\vUnNCVkeHUh?=
HL-60 NHH4U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjfIU5UUN3ME2wMlAzQTB6IN88US=> MkHvV2FPT0WU
KY821 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX1TWM2OD1yLkCyPVc2KM7:TR?= M1fCWnNCVkeHUh?=
ECC10 NHr5ZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLmTWM2OD1yLkCzO|kzKM7:TR?= MmrJV2FPT0WU
NCI-H720 NHL5fY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M331TGlEPTB;MD6wOFAyOSEQvF2= NYnmOHN7W0GQR1XS
QIMR-WIL M{T5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfaTWM2OD1yLkC0Nlg4KM7:TR?= NV3WeXVZW0GQR1XS
KG-1 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm2WpJsUUN3ME2wMlA1PDh4IN88US=> NVvxPY82W0GQR1XS
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PwRmlEPTB;MD6wOFY{OyEQvF2= NH22dWFUSU6JRWK=
ATN-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T6fWlEPTB;MD6wOFc{OyEQvF2= M4rXbHNCVkeHUh?=
RH-18 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\KTWM2OD1yLkC2NFQ5KM7:TR?= M2PCRXNCVkeHUh?=
EW-18 NVL5OlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;mZmdlUUN3ME2wMlA3QDRzIN88US=> NGe4SJhUSU6JRWK=
NB17 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XVTGlEPTB;MD6wO|EzPCEQvF2= M3nPRnNCVkeHUh?=
SK-NEP-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\OTWM2OD1yLkC3NlE{KM7:TR?= MUPTRW5ITVJ?
P12-ICHIKAWA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrNT|BKSzVyPUCuNFc4PzhizszN NV\xbWg3W0GQR1XS
KARPAS-45 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCzTWM2OD1yLkC3PFE2KM7:TR?= MX\TRW5ITVJ?
EW-3 M2XkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5NVBpUUN3ME2wMlA5ODV|IN88US=> MX7TRW5ITVJ?
NB13 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTNTWM2OD1yLkC4NlA{KM7:TR?= NGTSRVlUSU6JRWK=
NCI-H209 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjtNVdOUUN3ME2wMlA5PzB2IN88US=> MmflV2FPT0WU
NCI-H1092 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;wb2lEPTB;MD6xNFI4PSEQvF2= NUHyZo97W0GQR1XS
NH-12 NGrReZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[5TWM2OD1yLkGwO|Q1KM7:TR?= NYXjVG9PW0GQR1XS
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDKeVBKSzVyPUCuNVA5OzlizszN M1LmO3NCVkeHUh?=
KE-37 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHxN4JKSzVyPUCuNVE{PyEQvF2= MWLTRW5ITVJ?
MOLT-4 M3v3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSzVnAzUUN3ME2wMlE2OTZ7IN88US=> MlXJV2FPT0WU
CHP-134 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnEXIRKSzVyPUCuNVY{ODZizszN NWDaSldSW0GQR1XS
D-283MED Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\aTWM2OD1yLkG3Olg3KM7:TR?= MkjJV2FPT0WU
LU-135 M4PPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP2TWM2OD1yLkG4OVUzKM7:TR?= NFjKXI1USU6JRWK=
LU-134-A M3n0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7hTWM2OD1yLkG4OlcyKM7:TR?= NInDXJlUSU6JRWK=
EM-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILL[JpKSzVyPUCuNVk6OThizszN MWjTRW5ITVJ?
LU-139 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\ZTWM2OD1yLkKwOFk5KM7:TR?= NHq0eWlUSU6JRWK=
ALL-PO Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMkG5PFgh|ryP MV\TRW5ITVJ?
NB12 NUPlO|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMkOxNVUh|ryP NVPYdHdzW0GQR1XS
KP-N-YN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKfGlEPTB;MD6yN|U4OyEQvF2= MWrTRW5ITVJ?
BEN MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMkO5Olgh|ryP NYPyempkW0GQR1XS
HCC1569 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPGTG1KSzVyPUCuNlUyODZizszN NEOyc4hUSU6JRWK=
HuO9 NELFOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuxbIVKSzVyPUCuNlY4OTVizszN MX;TRW5ITVJ?
WM-115 M3rIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkPFNKSzVyPUCuNlc4OzhizszN NU\HO2tGW0GQR1XS
CCRF-CEM M4fiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwM{O1Nlkh|ryP M17GenNCVkeHUh?=
IST-SL1 NWS1cVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S4dGlEPTB;MD6zOVM1OyEQvF2= NF;vW3ZUSU6JRWK=
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PoUmlEPTB;MD6zOlQ2QSEQvF2= MontV2FPT0WU
COR-L88 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYc4U{UUN3ME2wMlM3PTRizszN Mn7jV2FPT0WU
DOHH-2 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jlTGlEPTB;MD60NVAzOyEQvF2= Mk\FV2FPT0WU
A704 M4\yZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLWdnk2UUN3ME2wMlQzPjdizszN NXHlOml3W0GQR1XS
KNS-81-FD NYftcm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXBd5lKSzVyPUCuOFQxOTdizszN NVzBeIRmW0GQR1XS
RPMI-8226 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwNEW2OVIh|ryP MoD4V2FPT0WU
TGBC24TKB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\CS2lEPTB;MD60OVc4QCEQvF2= NFT4Vo9USU6JRWK=
NCI-H1304 M4D0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzmeJE3UUN3ME2wMlQ3OTV5IN88US=> MUHTRW5ITVJ?
MOLT-13 M2HVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsNWJIUUN3ME2wMlQ3PjF|IN88US=> NIGwbZlUSU6JRWK=
EW-22 M3T6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNE[2O|Eh|ryP NYHMUGRiW0GQR1XS
MS-1 M3jKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHaNFB3UUN3ME2wMlQ3QTN|IN88US=> NHjEZ|BUSU6JRWK=
RMG-I NG\NOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vK[mlEPTB;MD60PVQ3PCEQvF2= NFHWRYtUSU6JRWK=
NTERA-S-cl-D1 M3PXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNUCwNVkh|ryP NGXxbXJUSU6JRWK=
NCI-H1048 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLoTWM2OD1yLkWwPVU{KM7:TR?= MlOwV2FPT0WU
SW1417 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHRdFJpUUN3ME2wMlU2PDN6IN88US=> NWPKbphiW0GQR1XS
DB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYezfpI{UUN3ME2wMlU4ODhizszN MV3TRW5ITVJ?
MEG-01 NEPCeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq2dIhKSzVyPUCuOVg{OiEQvF2= NFTEeJpUSU6JRWK=
EW-13 M3mwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i1cmlEPTB;MD61PFM1OSEQvF2= MoDlV2FPT0WU
LAMA-84 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnzW|k5UUN3ME2wMlU6OjB5IN88US=> M2LFWXNCVkeHUh?=
J-RT3-T3-5 M4HGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M125OWlEPTB;MD62NFgxQCEQvF2= MoLVV2FPT0WU
MOLT-16 M2C2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwNkWyOlQh|ryP M{e1Z3NCVkeHUh?=
DU-4475 MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkW0Nlch|ryP M4rxb3NCVkeHUh?=
HAL-01 M4ThPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zsfWlEPTB;MD63NlU1QSEQvF2= NVHHfIM{W0GQR1XS
RD MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWbXdKSzVyPUCuO|U5QTlizszN NUPEe4JnW0GQR1XS
OAW-28 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX1TWM2OD1yLke4N|ch|ryP MomxV2FPT0WU
HCC38 M3TOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHqTWM2OD1yLkiwNVkh|ryP M3jUWnNCVkeHUh?=
NMC-G1 M2j5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOEGxNlEh|ryP MmHRV2FPT0WU
EW-16 NHPIUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO0enEyUUN3ME2wMlgyOzJ6IN88US=> Mn\6V2FPT0WU
DU-145 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:2foEzUUN3ME2wMlg6QTJ|IN88US=> NVHoNGFNW0GQR1XS
HPAF-II NXrkS3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TR[WlEPTB;MD65NlYzQCEQvF2= Mn7lV2FPT0WU
A427 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOUOwNlIh|ryP M2HlWHNCVkeHUh?=
PA-1 NYHER5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwOUW2OFIh|ryP NETlfWNUSU6JRWK=
OAW-42 M3Oz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGPG9KSzVyPUCuPVYyPDZizszN MmrEV2FPT0WU
L-428 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwMEGyOUDPxE1? M1rBcXNCVkeHUh?=
COLO-824 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLROGxKSzVyPUGuNFE4ODhizszN M{K1Z3NCVkeHUh?=
P30-OHK MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PuW2lEPTB;MT6wOFY5QCEQvF2= MlH0V2FPT0WU
NCI-H2170 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwME[yN{DPxE1? MoTBV2FPT0WU
HCC2998 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PQZWlEPTB;MT6wO|E{PSEQvF2= NV;qPGRkW0GQR1XS
NB14 M1L3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3DXmIzUUN3ME2xMlE{PzR6IN88US=> NEDsSYRUSU6JRWK=
TGBC1TKB NHrXT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG3VGs{UUN3ME2xMlE1OTV{IN88US=> MXXTRW5ITVJ?
KP-N-YS NFnmUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[2e|lZUUN3ME2xMlE3OjN4IN88US=> M364cHNCVkeHUh?=
CAL-120 MoDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfCTWM2OD1zLkG2OFI6KM7:TR?= M{HEXnNCVkeHUh?=
SBC-1 NXj4PJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP3[3dKSzVyPUGuNVkxPTNizszN NXXtemNUW0GQR1XS
C32 M4K2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPqTWM2OD1zLkG5NFg5KM7:TR?= NX;JNJlWW0GQR1XS
HCC2157 NHLZO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwMUm0PVQh|ryP NUW1WmhOW0GQR1XS
COLO-792 M2XYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4frU2lEPTB;MT6yNFA4OSEQvF2= MmmzV2FPT0WU
ES7 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjuSphyUUN3ME2xMlI4QTVzIN88US=> MXfTRW5ITVJ?
HEL M3rmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfreGQ1UUN3ME2xMlMyODJ7IN88US=> M2LPdXNCVkeHUh?=
ES4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrtcJpKSzVyPUGuN|Q6QThizszN M3fzeHNCVkeHUh?=
NCI-SNU-1 M3\RWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD0RplKSzVyPUGuN|Y2PTVizszN M1HFXHNCVkeHUh?=
MDA-MB-415 NEjwOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEex[I1KSzVyPUGuN|g5PSEQvF2= Mn23V2FPT0WU
NCI-H2342 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;yTWM2OD1zLkSwNlY6KM7:TR?= M{\IPHNCVkeHUh?=
NB69 NEDHW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr3PIUzUUN3ME2xMlQ3OjdzIN88US=> MV\TRW5ITVJ?
D-247MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\EUmlEPTB;MT61NVEzOiEQvF2= M{KyOHNCVkeHUh?=
SCC-4 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jNWGlEPTB;MT61PVg5PyEQvF2= MYTTRW5ITVJ?
HuH-7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6wV4xKSzVyPUGuOlczQTNizszN MlG3V2FPT0WU
A388 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vRTmlEPTB;MT62PFczPCEQvF2= NI\BSnBUSU6JRWK=
Calu-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGwTWM2OD1zLkewOlk4KM7:TR?= MVTTRW5ITVJ?
NCI-H1648 NH35WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVraTI1SUUN3ME2xMlcyPDF6IN88US=> NXr6Sm9IW0GQR1XS
NCI-H2052 M1;wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHLTWM2OD1zLkeyNlAyKM7:TR?= NVXqNnkzW0GQR1XS
Ramos-2G6-4C10 NIr4dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO3TWM2OD1zLkezOlU3KM7:TR?= NEnhPW5USU6JRWK=
DEL NIjZTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDQTWM2OD1zLke0OlkzKM7:TR?= MUPTRW5ITVJ?
SNU-423 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qOWlEPTB;MT63PFE2PyEQvF2= MWnTRW5ITVJ?
COR-L23 NVfFOGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LzWmlEPTB;MT63PVg4PCEQvF2= MX7TRW5ITVJ?
OMC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwOE[wNVYh|ryP NGL1SGxUSU6JRWK=
EW-11 M3yzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfJb|BKSzVyPUGuPVU3PTdizszN M2DjdXNCVkeHUh?=
HSC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwOU[zOlUh|ryP NHfCTFRUSU6JRWK=
MLMA NUm4UFFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LCbWlEPTB;MT65OlY4PyEQvF2= MXfTRW5ITVJ?
RCM-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwMECzPVkh|ryP MWnTRW5ITVJ?
MFE-280 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwMEK4OFgh|ryP MXTTRW5ITVJ?
ES8 NHjxSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\3SnpKSzVyPUKuNlU1PzFizszN NHnjOlJUSU6JRWK=
TE-11 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfRTWM2OD1{LkK5OFc{KM7:TR?= NEH0SXhUSU6JRWK=
HuO-3N1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;1eHBuUUN3ME2yMlQ5PzhizszN NYjGOlRTW0GQR1XS
MHH-NB-11 NFq1ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HXSmlEPTB;Mj61NVE2QCEQvF2= M1LYRnNCVkeHUh?=
TGBC11TKB NH:4c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXRT3RKSzVyPUKuOVc3QDFizszN MmrBV2FPT0WU
HOP-92 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflSpl4UUN3ME2yMlU5PzR|IN88US=> MVvTRW5ITVJ?
IGR-1 M3XDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3rUHhKSzVyPUKuOlIxOzVizszN NWr3eoU5W0GQR1XS
GOTO NXu4b5hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfrTWM2OD1{Lk[1N|c4KM7:TR?= MkXwV2FPT0WU
NCI-H1650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXYTWM2OD1{LkeyNlE2KM7:TR?= M1[ySHNCVkeHUh?=
NCI-H1581 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJwN{m2PFEh|ryP NVvKUIxCW0GQR1XS
NCI-H2405 NWfncG43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TpSWlEPTB;Mj64Nlc5OiEQvF2= M4Dh[XNCVkeHUh?=
U-118-MG NIrRS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD4TJRGUUN3ME2yMlk3PDlzIN88US=> NFGzVYVUSU6JRWK=
DoTc2-4510 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle2TWM2OD1|LkCxOFE4KM7:TR?= M2rLe3NCVkeHUh?=
NCI-H596 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrE[oN2UUN3ME2zMlA1QTl5IN88US=> MX;TRW5ITVJ?
MPP-89 NIDrUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rBSmlEPTB;Mz6wOVY3PiEQvF2= Mmr1V2FPT0WU
GCIY MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELhe5lKSzVyPUOuNlA1QTFizszN NHrLXWhUSU6JRWK=
SW626 NFPpXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULTUYN1UUN3ME2zMlI1PTR|IN88US=> M3uzfnNCVkeHUh?=
OCI-AML2 NVPYVldHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXiTWM2OD1|LkOxNlczKM7:TR?= M2\IUHNCVkeHUh?=
NBsusSR M1fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[1ZmlEPTB;Mz6zOFk{QCEQvF2= M{fmTXNCVkeHUh?=
AN3-CA NYrDUnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTnTWM2OD1|LkS0NlM5KM7:TR?= Mo[1V2FPT0WU
EFM-19 NHexSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1|LkS4N|M6KM7:TR?= NVfy[IlOW0GQR1XS
RVH-421 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17RcmlEPTB;Mz61Olg4PyEQvF2= M2CzdnNCVkeHUh?=
5637 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;RXYRVUUN3ME2zMlYyOTB|IN88US=> NV\KbWVuW0GQR1XS
PANC-08-13 M17hRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPoTWM2OD1|Lk[zOFczKM7:TR?= NVLWSG5KW0GQR1XS
H9 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTzVI9vUUN3ME2zMlY4OTR2IN88US=> M{jNbHNCVkeHUh?=
KARPAS-299 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vjUWlEPTB;Mz62O|M3OSEQvF2= MVzTRW5ITVJ?
TE-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwN{C3NFkh|ryP NWTvdlZ2W0GQR1XS
NOS-1 M{HYe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Fe2dKUUN3ME2zMlc6QDN2IN88US=> NVjYT49JW0GQR1XS
HH NXvnOXRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGeyUIpKSzVyPUOuPFM5PjhizszN NWHHcXdEW0GQR1XS
769-P MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLxNnZKSzVyPUOuPFk2OSEQvF2= NFPjS2ZUSU6JRWK=
CHP-212 NHXaV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwOUK1OFkh|ryP MXvTRW5ITVJ?
NCI-H82 NYLqT4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfDTWM2OD1|Lkm1PVM3KM7:TR?= M{DZXnNCVkeHUh?=
Mo-T M4fB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfHcXB{UUN3ME20MlA1OzF{IN88US=> NG\TfoNUSU6JRWK=
BB65-RCC Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn3ZVllUUN3ME20MlA1Ozl7IN88US=> Mn71V2FPT0WU
SW1990 M3X3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T0WmlEPTB;ND6wOVkxQCEQvF2= Ml23V2FPT0WU
LK-2 NVX4UGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWxTWM2OD12LkGxNlk{KM7:TR?= NFLwRnpUSU6JRWK=
ES5 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzLOZpOUUN3ME20MlE{QTh3IN88US=> Mn6yV2FPT0WU
JVM-3 NGrKVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi5cIJUUUN3ME20MlE5OjJ{IN88US=> NVLzOI1zW0GQR1XS
RPMI-7951 NVu0[oM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke0TWM2OD12LkKyOFE{KM7:TR?= NEm5[WVUSU6JRWK=
Calu-6 NYjFZ3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXmb5ZKSzVyPUSuNlc5QDFizszN MmHhV2FPT0WU
LC-2-ad NXK5flhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPYXGlHUUN3ME20MlI6PTZ6IN88US=> NHL0V|BUSU6JRWK=
SW954 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPiTWM2OD12LkK5OlYh|ryP NWX0RVZwW0GQR1XS
H-EMC-SS M4iyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\VcodKSzVyPUSuN|E5OzFizszN MUnTRW5ITVJ?
ES3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLEO2VKSzVyPUSuN|U1PDFizszN NWHWT|ZLW0GQR1XS
no-11 NUnYN5N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\mUplKSzVyPUSuN|U2PTRizszN NV3GWWFyW0GQR1XS
LAN-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX1[YlKSzVyPUSuOFUyQDlizszN MWPTRW5ITVJ?
FTC-133 MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3UGlEPTB;ND61N|k2KM7:TR?= NUT2bItXW0GQR1XS
8505C NF34UldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnITWM2OD12LkW0NlMh|ryP MnvIV2FPT0WU
SW620 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHZcoRKSzVyPUSuOVcxPTdizszN NE\3bWxUSU6JRWK=
BCPAP NV7QXWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvQW2lKSzVyPUSuOlM1QDFizszN NXrhPW8xW0GQR1XS
SK-LU-1 NU\vSpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v1VGlEPTB;ND62OlA5QSEQvF2= MnTFV2FPT0WU
NCI-H1623 NWDiVmZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm1UWFWUUN3ME20MlcxOjJ6IN88US=> M4rLNXNCVkeHUh?=
C2BBe1 NU\SO2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme0TWM2OD12Lke0NFA5KM7:TR?= NGXHfGNUSU6JRWK=
GP5d NE\nTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvNmlEPTB;ND63PFM5QCEQvF2= NFO5UXlUSU6JRWK=
NB6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HRT2lEPTB;ND64OlIxPCEQvF2= MV3TRW5ITVJ?
MDA-MB-157 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT0TWM2OD12Lki4O|Yh|ryP NEnZZ4RUSU6JRWK=
UMC-11 M1X5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRwOEi5OlQh|ryP MUnTRW5ITVJ?
HCC1419 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jtfGlEPTB;ND65NFA3OyEQvF2= MmPOV2FPT0WU
NCI-H2029 NXz2[ZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTRwOUSxPFUh|ryP M{DPdnNCVkeHUh?=
LXF-289 NXrGeJkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV35Z4pZUUN3ME21MlA{PzF7IN88US=> MWfTRW5ITVJ?
KINGS-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTVwMEe3OFQh|ryP MmTkV2FPT0WU
HD-MY-Z Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLGTWM2OD13LkKzPVY6KM7:TR?= Ml;SV2FPT0WU
ESS-1 M1y0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfsPGU1UUN3ME21MlI2PTl5IN88US=> NIPEboFUSU6JRWK=
GI-1 NIXy[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rtb2lEPTB;NT6yO|kzPiEQvF2= NFq3UINUSU6JRWK=
RPMI-2650 NEXldnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT1bmVHUUN3ME21MlM3OTZizszN NH7PNZhUSU6JRWK=
IA-LM M{H1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6zSmRKSzVyPUWuN|k5PzFizszN NYeydGdxW0GQR1XS
KP-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTVwNE[zN|Qh|ryP NHr1N|VUSU6JRWK=
G-402 NWTjSo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxTWM2OD13LkWxPFY2KM7:TR?= MV3TRW5ITVJ?
OS-RC-2 M4DBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD13LkWyOlA1KM7:TR?= MXnTRW5ITVJ?
NCI-H1155 NYrUPHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjGVFlbUUN3ME21MlU1QTV3IN88US=> MV3TRW5ITVJ?
OE19 NWHmUJBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwNki2NlQh|ryP MkfJV2FPT0WU
U-2-OS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXvTWM2OD13Lki5NFE{KM7:TR?= NWSwPGR5W0GQR1XS
SCC-15 NGjGdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwOUO2OlIh|ryP MYfTRW5ITVJ?
NCI-H630 NUjlc3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvmTWM2OD13Lkm5OFA1KM7:TR?= MWHTRW5ITVJ?
PFSK-1 NF71S|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r6SWlEPTB;Nj6wOVI2QSEQvF2= NFnGeVNUSU6JRWK=
NCI-H1770 NXP0bGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZwMkC4O|Qh|ryP M3vGbXNCVkeHUh?=
SK-MEL-3 M32wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZwNEK5NVUh|ryP MUPTRW5ITVJ?
LB1047-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvbXEyUUN3ME22MlQ4PjJ3IN88US=> MkfaV2FPT0WU
NCI-H446 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjDSYNKSzVyPU[uOlI6OjVizszN NWDHR2VxW0GQR1XS
SW780 MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLNRWpoUUN3ME22MlcxOTh3IN88US=> Mly2V2FPT0WU
NEC8 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTZwN{[2N{DPxE1? NIDL[pBUSU6JRWK=
NOMO-1 NFLYTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT0clZKSzVyPU[uO|gyOTFizszN Ml3qV2FPT0WU
COLO-668 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTZwOESzPFch|ryP M{HO[HNCVkeHUh?=
MC116 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\jTWM2OD14LkmzPFk4KM7:TR?= MlzRV2FPT0WU
HCC1937 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D2U2lEPTB;Nj65PVI2OSEQvF2= MmG4V2FPT0WU
NCI-N87 NWPueG97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLZTWM2OD15LkG5Nlk{KM7:TR?= M{joZXNCVkeHUh?=
COLO-320-HSR NVLsZpZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;LWGlEPTB;Nz6yNlc{QCEQvF2= MX7TRW5ITVJ?
HCC1806 M37ZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTdwMk[wOFQh|ryP MkTaV2FPT0WU
OVCAR-3 NXj5PIppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm2TWM2OD15LkOzNFM5KM7:TR?= NEDKcoFUSU6JRWK=
NUGC-3 M{XafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi0cIVoUUN3ME23MlM6Pjl2IN88US=> NYnqfZhTW0GQR1XS
SW1783 M3e2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELCOGVKSzVyPUeuOFMyPzVizszN M4HZXXNCVkeHUh?=
GCT M1PJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCOmlEPTB;Nz61OlkxPiEQvF2= MY\TRW5ITVJ?
NCI-H2126 NXjlc5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD6TWM2OD15LkezOlI2KM7:TR?= MYXTRW5ITVJ?
MEL-HO NVO0TIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\4RWlEPTB;Nz63O|A2PCEQvF2= NVvJSGZYW0GQR1XS
CAPAN-1 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTdwN{ezOVch|ryP MX\TRW5ITVJ?
SW756 NGLJU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXHNHFIUUN3ME23Mlc5OzN|IN88US=> MkKyV2FPT0WU
SKG-IIIa NFzvZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvzTWM2OD15LkixPFkzKM7:TR?= MmXHV2FPT0WU
HCE-T NVnJd2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m2PWlEPTB;Nz64O|c5OyEQvF2= M3X1OHNCVkeHUh?=
Ca-Ski M4rncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjR[oxKSzVyPUeuPVk{QDNizszN MmL5V2FPT0WU
COLO-684 M1\o[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ITWM2OD16LkCxPFE5KM7:TR?= NWP3XphsW0GQR1XS
KYSE-70 M4LD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHHTWM2OD16LkC3O|I6KM7:TR?= NV3DN2ptW0GQR1XS
TI-73 NGjyZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jwb2lEPTB;OD6yOVg2OSEQvF2= NGPvemxUSU6JRWK=
BT-20 NF;0dHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD5TWM2OD16LkK2NFUzKM7:TR?= MmKzV2FPT0WU
MHH-ES-1 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRThwNUG4N|Qh|ryP NWq4dFJkW0GQR1XS
TE-12 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jGSmlEPTB;OD61PVk{OSEQvF2= M3HHVXNCVkeHUh?=
YH-13 M1P4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPmfXhKSzVyPUiuOlExODhizszN M2PhdHNCVkeHUh?=
SF126 NXzq[W5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3XTWM2OD16LkizPFY2KM7:TR?= NE\ZbHpUSU6JRWK=
J82 NFjjUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jMdmlEPTB;OD65NFA{QCEQvF2= NUfpOlNjW0GQR1XS
RCC10RGB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwOUm1OlEh|ryP MoGxV2FPT0WU
SK-UT-1 M1nJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTlwMES5OFUh|ryP MlzpV2FPT0WU
LB2241-RCC MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKwPWJKSzVyPUmuNVkyOzdizszN MlvEV2FPT0WU
LB996-RCC NGHwcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfOOpBKSzVyPUmuNVk5QSEQvF2= M3nVO3NCVkeHUh?=
EPLC-272H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTlwM{e2OVch|ryP MmDxV2FPT0WU
CTV-1 NUn3WoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPLdHdxUUN3ME25MlU3PTN{IN88US=> NYnCOlhbW0GQR1XS
HSC-2 NH;XelZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17RVWlEPTB;OT61O|U2KM7:TR?= M3\yWHNCVkeHUh?=
SK-MEL-28 MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTNSpppUUN3ME25MlYyQDl|IN88US=> MmfsV2FPT0WU
MMAC-SF MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LwSWlEPTB;OT62PFc2KM7:TR?= NILMeohUSU6JRWK=
CP50-MEL-B NUjo[opVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwN{W3PFIh|ryP MknYV2FPT0WU
HT-1080 M{flWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD0TWM2OD17Lke3O|M6KM7:TR?= MUHTRW5ITVJ?
HEC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFyLkOzOVIh|ryP NHrnNJdUSU6JRWK=
AGS M{Cxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\NSpdCUUN3ME2xNE4{PzRizszN M4ruenNCVkeHUh?=
GAMG NGGxSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fTdGlEPTB;MUCuOVE3OiEQvF2= Ml3jV2FPT0WU
SW48 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7YTWM2OD1zMD61NVg6KM7:TR?= MYPTRW5ITVJ?
U031 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\nTWM2OD1zMD61PVA5KM7:TR?= M33iU3NCVkeHUh?=
OVCAR-5 NUPHZnJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFyLk[0Nlkh|ryP MmHDV2FPT0WU
SF295 NUHKVG54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtOlVmUUN3ME2xNE43PzB2IN88US=> NXHPZWp1W0GQR1XS
BHT-101 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjKT4RYUUN3ME2xNE44OTd5IN88US=> MmLBV2FPT0WU
VMRC-RCZ M2nFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13NUGlEPTB;MUGuN|IxOSEQvF2= MV7TRW5ITVJ?
ACHN NF\MR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG4[lJKSzVyPUGxMlQzOTFizszN MXjTRW5ITVJ?
NCI-H526 M1TtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4izeGlEPTB;MUGuOVA1OyEQvF2= NIfSSIdUSU6JRWK=
MN-60 NULPRmtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFzLkWzPUDPxE1? M2PBcnNCVkeHUh?=
NCI-H2291 NWDEXXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFzLkW0OlYh|ryP MlXXV2FPT0WU
SCC-25 M37jbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFzLke1OVYh|ryP MmLEV2FPT0WU
SK-MEL-2 NFfXZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLiTWM2OD1zMT63OlM4KM7:TR?= NFzE[I9USU6JRWK=
SN12C Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\xTWM2OD1zMT65N|U2KM7:TR?= M1fPNXNCVkeHUh?=
NCI-H69 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF{LkSyN|Qh|ryP NUfkb3V3W0GQR1XS
ME-180 M{WxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF{LkewOVQh|ryP Ml\xV2FPT0WU
MC-IXC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyVFBKSzVyPUGyMlc2OThizszN NX\F[3Z1W0GQR1XS
NCI-H2347 NI\RbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO5RopKSzVyPUGyMlc3OTRizszN NIrLPXlUSU6JRWK=
M059J NUnXfoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjETWM2OD1zMj63O|I4KM7:TR?= MnrQV2FPT0WU
A2058 M3K0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HWVmlEPTB;MUKuPFY5OSEQvF2= M{LpT3NCVkeHUh?=
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P6fmlEPTB;MUKuPFc5PSEQvF2= MkXDV2FPT0WU
Ca9-22 NYrxOINQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XicmlEPTB;MUKuPVQ2OSEQvF2= MVrTRW5ITVJ?
KNS-42 NWe3cJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nDWGlEPTB;MUKuPVk5PCEQvF2= MXfTRW5ITVJ?
LoVo M3TLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX2TZIyUUN3ME2xN{4zOzF|IN88US=> M3za[XNCVkeHUh?=
AM-38 NVToRlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLiTWM2OD1zMz6yOVY3KM7:TR?= MnO0V2FPT0WU
NB5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvrTWM2OD1zMz6zO|UzKM7:TR?= NXfES21rW0GQR1XS
L-363 NFWzbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF|LkSwN|Mh|ryP MVjTRW5ITVJ?
SK-MEL-30 NIr6[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP6bmhKSzVyPUG0MlA3PDVizszN NH31dZBUSU6JRWK=
NCI-H1563 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2Lk[wN|kh|ryP MXLTRW5ITVJ?
NCI-H2228 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HsS2lEPTB;MUSuOlA4PyEQvF2= MnnqV2FPT0WU
MFM-223 NHLIWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLPTWM2OD1zNT6xPFE{KM7:TR?= NVizNXVZW0GQR1XS
LB831-BLC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDse2ozUUN3ME2xOU4zPzZ5IN88US=> M1flV3NCVkeHUh?=
SW872 M3i4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jE[mlEPTB;MUWuN|A5PiEQvF2= NVXwcGlDW0GQR1XS
NCI-H522 NYLFXJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrVWlEPTB;MUWuN|MxPiEQvF2= MUjTRW5ITVJ?
EW-1 M4XLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ISmNKSzVyPUG1MlU1PjJizszN NX3RO4g4W0GQR1XS
HN NUXreYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS1TWM2OD1zNT61PVQzKM7:TR?= M2\he3NCVkeHUh?=
SW837 NVrEZXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF3Lke4OFch|ryP NIXnV4VUSU6JRWK=
SCC-9 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofPTWM2OD1zNT64NVE1KM7:TR?= MU\TRW5ITVJ?
MKN7 NH3vO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF3Lkm3N|Ih|ryP M3TnOHNCVkeHUh?=
KYSE-410 NFfhc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD1zNj61PVEh|ryP MnLkV2FPT0WU
SK-N-DZ M3K3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHSendvUUN3ME2xOk43OTF4IN88US=> MXTTRW5ITVJ?
COR-L105 M3T1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq1TWM2OD1zNj62OVI5KM7:TR?= NV;NfW5JW0GQR1XS
LB2518-MEL NUXT[40zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXzSIREUUN3ME2xOk45Ozh7IN88US=> NFT1NmRUSU6JRWK=
OVCAR-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrMTWM2OD1zNj64PFYzKM7:TR?= NVLzcHFVW0GQR1XS
TK10 M{fZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF4Lkm0O|Mh|ryP NWrQSXlyW0GQR1XS
KNS-62 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF4Lkm3O|ch|ryP NFmzTYNUSU6JRWK=
RPMI-8866 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzy[2NKSzVyPUG3MlE4OzJizszN NHzRUXRUSU6JRWK=
HuP-T4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF5LkK0PVUh|ryP NHHnbmhUSU6JRWK=
CGTH-W-1 NFX1UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF5LkWyNVkh|ryP NXLsVHU1W0GQR1XS
T-24 M4C2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fXVWlEPTB;MUeuOVM1PyEQvF2= M2\uOHNCVkeHUh?=
HT-3 NFK2cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnTdZluUUN3ME2xO{42QTF2IN88US=> M2TuS3NCVkeHUh?=
KS-1 NGDlR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XmN2lEPTB;MUeuOlc{KM7:TR?= NHzWPGNUSU6JRWK=
NCI-H1792 NIjSWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHDcGhKSzVyPUG3Mlc6QCEQvF2= NF3WVFRUSU6JRWK=
ABC-1 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPWeYg1UUN3ME2xO{45OTRzIN88US=> NFLUcZlUSU6JRWK=
BPH-1 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHZXHNKSzVyPUG4MlE3QDVizszN M3LTe3NCVkeHUh?=
A431 M4jERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD3TWM2OD1zOD60NVI4KM7:TR?= M4i1[3NCVkeHUh?=
T98G M1jHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrEbXpsUUN3ME2xPE42OTV5IN88US=> M1;5OnNCVkeHUh?=
BHY MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF6Lki2PUDPxE1? M37MUHNCVkeHUh?=
Capan-2 M2LEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF6LkmwO|gh|ryP MXPTRW5ITVJ?
MDA-MB-175-VII MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HRN2lEPTB;MUiuPVIxQSEQvF2= M4j3e3NCVkeHUh?=
CAL-27 M1jQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD1zOT6wOFg4KM7:TR?= M2r1N3NCVkeHUh?=
AsPC-1 NHvpVI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7xSmJ1UUN3ME2xPU45PjV5IN88US=> MYjTRW5ITVJ?
KU812 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LmVWlEPTB;MUmuPVU4OyEQvF2= NH;BdXpUSU6JRWK=
NCI-H441 NV7Cc|dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1TWM2OD1{MD6wNFEh|ryP MoLmV2FPT0WU
Mewo MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTOfoduUUN3ME2yNE4yOjh6IN88US=> M4f2OHNCVkeHUh?=
SK-MEL-24 NFnzeVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fxPWlEPTB;MkCuNVQ4PyEQvF2= NGr6[|NUSU6JRWK=
NCI-H727 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MornTWM2OD1{MD6yO|A1KM7:TR?= NIXydYVUSU6JRWK=
EKVX M2fhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrxb4lKSzVyPUKwMlYxPiEQvF2= MVTTRW5ITVJ?
RT-112 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nCcGlEPTB;MkCuOlEzOiEQvF2= MW\TRW5ITVJ?
CAMA-1 M{PQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG1eFNKSzVyPUKwMlk5ODNizszN MWTTRW5ITVJ?
SW900 M4f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TE[mlEPTB;MkGuNFE1QSEQvF2= NXHQU2E{W0GQR1XS
NCI-H23 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJzLkGyO|ch|ryP NIPMbJJUSU6JRWK=
SK-PN-DW M{njNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfGdnpKSzVyPUKxMlE3PDlizszN NIXlbIhUSU6JRWK=
BB30-HNC NYrlemlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\CVmlEPTB;MkGuNlc1PSEQvF2= NELIZnBUSU6JRWK=
VM-CUB-1 Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDmTWM2OD1{MT6zOVM3KM7:TR?= NYfyOoI5W0GQR1XS
IST-MEL1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLXTWM2OD1{MT6zOlkzKM7:TR?= MWDTRW5ITVJ?
CTB-1 NV;qd|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJzLkS3OVUh|ryP M3zm[XNCVkeHUh?=
LCLC-103H MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrEWFRxUUN3ME2yNk4yPTh{IN88US=> NFP6OGFUSU6JRWK=
PANC-03-27 NX;OZXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQXmlEPTB;MkKuOVE3QSEQvF2= NUTmb|hQW0GQR1XS
HTC-C3 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH5TWM2OD1{Mj61OVU2KM7:TR?= Mo\oV2FPT0WU
TE-8 M2nwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID4UlZKSzVyPUKzMlI2PjVizszN M1HsWnNCVkeHUh?=
NCI-H292 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHyyTmZKSzVyPUK1MlM2OzZizszN M{G2WHNCVkeHUh?=
COLO-680N NYj4bJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LSVWlEPTB;MkWuOlMzQSEQvF2= M2rTN3NCVkeHUh?=
KYSE-520 NE\2XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hs[2lEPTB;MkWuOlQ1KM7:TR?= MmPuV2FPT0WU
NB10 M2XOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ4LkOxNVch|ryP M4LSZ3NCVkeHUh?=
NCI-H661 NYfD[VhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLRfJFKSzVyPUK2MlQ4OTNizszN MUDTRW5ITVJ?
GMS-10 NXG3Vm92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\LTWM2OD1{Nj64OlM5KM7:TR?= NH;sOmtUSU6JRWK=
NCI-H2122 NYf2XG5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\PTWM2OD1{Nj65PVk5KM7:TR?= NV\4fm1mW0GQR1XS
OVCAR-8 M3vKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTSNFlyUUN3ME2yO{4xPjN6IN88US=> NHi5SZNUSU6JRWK=
DJM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmixTWM2OD1{Nz6xOFU1KM7:TR?= M37MVXNCVkeHUh?=
UACC-893 NYnlXYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL6TWM2OD1{Nz65PFc5KM7:TR?= MmD1V2FPT0WU
C8166 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfMcWdoUUN3ME2yPE43QTN6IN88US=> MmHqV2FPT0WU
NCI-H1693 NYT2O|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ6Lk[5O|Uh|ryP NYPs[GN6W0GQR1XS
TYK-nu M2\YZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fPPGlEPTB;M{CuNFM1PSEQvF2= NVnnepNpW0GQR1XS
SW1710 NEPjZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XwRWlEPTB;M{CuNVI3KM7:TR?= NUfjeI5kW0GQR1XS
A375 NWjKc3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm0RoxKSzVyPUOwMlMzPDNizszN MnzNV2FPT0WU
HMV-II Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNzLkO1PVIh|ryP MWDTRW5ITVJ?
NCI-H2087 M2PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnK[nZKSzVyPUOxMlY{PTJizszN M3nMPXNCVkeHUh?=
CAL-54 NXzSNHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf1cYNKSzVyPUOxMlczPDFizszN Mnr6V2FPT0WU
HCC70 NFvxblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN{LkGzPFch|ryP NXX1[5NPW0GQR1XS
ES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDS2lEPTB;M{KuN|A3OiEQvF2= MX7TRW5ITVJ?
NCI-H1355 NVy4PG1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN|LkKwOEDPxE1? MV7TRW5ITVJ?
CFPAC-1 NWrrV4FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfL[ZdKSzVyPUOzMlI{OzJizszN MXXTRW5ITVJ?
MKN28 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzmTFE3UUN3ME2zN{4{QDB7IN88US=> M{nDXHNCVkeHUh?=
HDLM-2 NF3kUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fORmlEPTB;M{OuOlk{OSEQvF2= MX3TRW5ITVJ?
PANC-10-05 M3rzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PZb2lEPTB;M{SuNVAyPCEQvF2= M2XuUnNCVkeHUh?=
SAS M37nW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPKTWM2OD1|ND60OVY2KM7:TR?= M2DrZnNCVkeHUh?=
HCC1395 M1\JTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr4TWM2OD1|ND63NVg3KM7:TR?= MmLiV2FPT0WU
8305C M{TaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzsfWhKSzVyPUO1Mlg1OTVizszN NIm4fI5USU6JRWK=
KM12 NXLuWZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXh[IpKSzVyPUO2Mlc2PDdizszN MnPUV2FPT0WU
SW1116 M2C5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN5LkW5PVIh|ryP M3XmNHNCVkeHUh?=
SK-MEL-1 M{HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjRUohKSzVyPUO4MlM{QDlizszN NFvqPYVUSU6JRWK=
HCC2218 NUHEdWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN6Lk[1NVkh|ryP MnTMV2FPT0WU
T84 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvFcWFKSzVyPUO4Mlc1ODlizszN MmHpV2FPT0WU
ETK-1 NHW5dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SzcGlEPTB;M{muNFIzKM7:TR?= M3HwVXNCVkeHUh?=
COLO-800 NYewXplPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN7LkO4Olgh|ryP MmTVV2FPT0WU
CAL-12T NF7ycGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojNTWM2OD1|OT61NlgyKM7:TR?= MWLTRW5ITVJ?
ACN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HwemlEPTB;NECuOFkyOSEQvF2= M3vMfXNCVkeHUh?=
SJSA-1 M3LVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPTTWM2OD12MT6xOVk3KM7:TR?= MUHTRW5ITVJ?
PSN1 NUT0eXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm5ZZF3UUN3ME20NU4yPzR7IN88US=> NFnUOmFUSU6JRWK=
D-566MG NWr2Rm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYft[XZLUUN3ME20NU4zODh4IN88US=> NIPvS4lUSU6JRWK=
EGI-1 NH;ZVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDtd|BKSzVyPUSyMlQzQCEQvF2= M1PHOnNCVkeHUh?=
A204 M4fqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz5cVc6UUN3ME20Nk43Ozh6IN88US=> M2mybnNCVkeHUh?=
Saos-2 M4jZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDqUnM2UUN3ME20Nk45OzZ7IN88US=> MlT1V2FPT0WU
SNU-C2B NGPrUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR|Lk[4O|gh|ryP M{DvV3NCVkeHUh?=
HLE M1nnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\RcmFQUUN3ME20OE4xQDV4IN88US=> Moe2V2FPT0WU
SW1463 NXPwSYY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVPGlEPTB;NESuPVk4OSEQvF2= NV3oTXR5W0GQR1XS
DSH1 M{n6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR3LkCwN|Mh|ryP Mme5V2FPT0WU
MCF7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR3LkWwOVEh|ryP NWXCO4JqW0GQR1XS
K5 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTR3Lkm0NFUh|ryP MV\TRW5ITVJ?
NCI-H358 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR5LkKxOUDPxE1? MnTkV2FPT0WU
NCI-H2030 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTR5LkKzO|Qh|ryP M{Xvb3NCVkeHUh?=
SW948 NWjQR3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhSHFoUUN3ME20O{41PjRizszN NV7he2FlW0GQR1XS
BALL-1 NHTreoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjhbFY1UUN3ME20O{43OTZ6IN88US=> NV;QW|FpW0GQR1XS
TE-9 M4fUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLETWM2OD12Nz65OVgyKM7:TR?= NHLOS4hUSU6JRWK=
SK-N-FI MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS5TWM2OD12OD6wN|U5KM7:TR?= M{jO[XNCVkeHUh?=
KALS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;lNWlEPTB;NEiuNVI5QSEQvF2= NWjHeFhQW0GQR1XS
HO-1-N-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPxTWM2OD12OD63OFQ2KM7:TR?= NUnT[oRuW0GQR1XS
NCI-H2452 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPkcXRKSzVyPUS5MlEyPTJizszN MlPrV2FPT0WU
OC-314 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHtTWM2OD12OT62PFM1KM7:TR?= NIC4WlhUSU6JRWK=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
体内研究 用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
+ 展开

激酶实验:

用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验：

[1]
+ 展开
  • Cell lines: SCLC 细胞系
  • Concentrations: 0-1 μM
  • Incubation Time: 48小时
  • Method:

    人类肿瘤细胞系在37oC 含5% CO2环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。


    (Only for Reference)
动物实验：

[1]
+ 展开
  • Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠
  • Formulation: ABT-263在10% 乙醇, 30% 聚乙二醇400, 及60% Phosal 50 PG中制成
  • Dosages: 100 mg/kg/d
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+corn oil
 7mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 974.61
化学式

C47H55ClF3N5O6S3
CAS号 923564-51-6
储存条件 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Recruiting Advanced Lung Non-Squamous Non-Small Cell Carcinoma|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.T790M|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT00887757 Completed Solid Tumors AbbVie|Genentech Inc. September 2009 Phase 1
NCT00888108 Completed Solid Tumor Abbott|Genentech Inc. July 2009 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • 回答：

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • 问题 2：

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • 回答：

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Selleck产品目录册

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

  • 选择性强的Bcl-2抑制剂

    ABT-199 (GDC-0199) : Bcl-2-selective, Ki<0.01 nM.

  • 用于临床的Bcl-2抑制剂

    Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • 最新的Bcl-2家族激活剂

    BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • 经典的Bcl-2抑制剂

    ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

相关Bcl-2产品

  • A-1210477 New

    A-1210477是一种有效的选择性MCL-1抑制剂，Ki和IC50分别为0.454 nM 和 26.2 nM，选择性比作用于其他Bcl-2家族成员高100多倍。

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) 是一种口服生物有效的MDM2拮抗剂，Ki为0.88 nM。Phase 1。

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199)是一种Bcl-2选择性抑制剂，无细胞试验中Ki为<0.01 nM，比作用于Bcl-xL和Bcl-w选择性高4800倍以上，对Mcl-1没有抑制活性。Phase 3。

    Features:ABT-263 (Navitoclax)的重组

  • ABT-737

    ABT-737是一种BH3模拟抑制剂，作用于Bcl-xL，Bcl-2和Bcl-w，无细胞试验中EC50分别为78.7 nM，30.3 nM和197.8 nM；但对Mcl-1， Bcl-B及Bfl-1没有抑制作用。Phase 2。

    Features:ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。

  • UMI-77

    UMI-77是一种选择性Mcl-1抑制剂，Ki为490 nM，表现出高于Bcl-2家族其它成员的选择性。

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)是一种Bcl-2拮抗剂，无细胞试验中Ki为0.22 μM，可以协助抑制MCL-1介导的抗细胞凋亡作用。Phase 3。

    Features:Obatoclax是有应用前景的小分子Bcl-2拮抗剂，抑制Bcl-2蛋白家族所有相关的膜结构，包括 Mcl-1。

  • TW-37

    TW-37是一种新型的非肽类抑制剂，作用于重组Bcl-2，Bcl-xL和Mcl-1，无细胞试验中Ki分别为0.29 μM， 1.11 μM和0.26 μM。

    Features:TW-37是新型非肽类小分子 Bcl-2抑制剂。

  • Sabutoclax

    Sabutoclax是一种pan-Bcl-2抑制剂，作用于Bcl-xL， Bcl-2， Mcl-1和Bfl-1，IC50分别为0.31 μM， 0.32 μM， 0.20 μM和0.62 μM。

  • AT101

    AT101，是醋酸棉酚的R-(-)对映体，与Bcl-2，Bcl-xL和Mcl-1结合，无细胞试验中Ki为0.32 μM，0.48 μM 和 0.18 μM；不抑制BIR3域和BID。Phase 2。

Tags: 购买Navitoclax (ABT-263) | Navitoclax (ABT-263)供应商 | 采购Navitoclax (ABT-263) | Navitoclax (ABT-263)价格 | Navitoclax (ABT-263)生产 | 订购Navitoclax (ABT-263) | Navitoclax (ABT-263)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID